Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
My Near-Perfect Retirement Dividend Portfolio
07:30am, Friday, 24'th Jan 2025
Low-volatility, dividend growth stocks offer long-term outperformance and a favorable risk profile, despite lower yields during bull markets. Dividend growth portfolios can significantly increase yiel
Is AbbVie Stock a Buy?
05:48am, Friday, 24'th Jan 2025
Pharmaceutical powerhouse AbbVie (ABBV 0.87%) has been a beast since it spun off from Abbott Laboratories in 2012. Over the past decade, the stock has averaged a dividend yield of 3.5% while raising i
What Can The Dividend Kings Deliver In 2025?
03:14am, Friday, 24'th Jan 2025
The Dividend Kings underperformed the broad U.S. equity market in 2024, achieving a 5.53% total return compared to the S&P 500's 24.89%. 2024 returns for the Dividend Kings were primarily driven by ea
AbbVie Completes Acquisition of Nimble Therapeutics
09:16am, Thursday, 23'rd Jan 2025
Acquisition adds potential novel oral peptide IL23R inhibitor for psoriasis as well as a peptide synthesis, screening and optimization platform to strengthen AbbVie's pipeline and R&D capabilities NOR
AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology
09:00am, Thursday, 23'rd Jan 2025
Collaboration leverages AbbVie's expertise in oncology and immunology drug development and Neomorph's leading molecular glue discovery platform Neomorph to receive an upfront payment and is eligible
Got $1,500? 3 Healthcare Stocks to Buy and Hold Forever
06:22pm, Tuesday, 21'st Jan 2025
Many products sold by companies aren't must-have items. However, healthcare is a necessity.
Got $500? 2 Pharmaceutical Stocks to Buy and Hold Forever
07:10am, Tuesday, 21'st Jan 2025
You've probably heard this before: Pharmaceutical stocks can bring an element of safety to your portfolio. Why is this the case?
3 Unstoppable Dividend-Growth Stocks Yielding More Than 3% That Income-Seeking Investors Want to Buy in 2025 and Hold Forever
04:17am, Tuesday, 21'st Jan 2025
Investors seeking a steadily growing passive income stream want to turn their heads toward the healthcare sector. Unlike with enterprise software sales or consumer goods, spending on healthcare tends
Top 4 Immunology Stocks Poised For Growth In 2025
04:54pm, Sunday, 19'th Jan 2025
This article will reveal an in-depth analysis of drugs being developed to combat immunological disorders. Big Pharma is keenly interested in the global immunology drugs market, which is anticipated to
Income & Growth: 3 Of The Best Dividend Stocks For Any Market
07:30am, Friday, 17'th Jan 2025
Inflation continues to erode purchasing power, and recent volatility highlights the uncertainty in inflation trends. Despite this, long-term investors can still find opportunities. In an unpredictable
Why the Market Dipped But AbbVie (ABBV) Gained Today
06:51pm, Thursday, 16'th Jan 2025
In the most recent trading session, AbbVie (ABBV) closed at $173.70, indicating a +1.37% shift from the previous trading day.
AbbVie Inc. (ABBV) J.P. Morgan 43rd Annual Healthcare Conference (Transcript)
02:28pm, Wednesday, 15'th Jan 2025
AbbVie Inc. (NYSE:ABBV ) J.P. Morgan 43rd Annual Healthcare Conference January 15, 2025 11:15 AM ET Company Participants Rob Michael - Chief Executive Officer Scott Reents - Executive Vice President,
AbbVie to 'commit less capital' towards psychiatric drugs, CEO says
12:10pm, Wednesday, 15'th Jan 2025
AbbVie will commit less capital towards experimental medicines for psychiatric disease, CEO Robert Michael said at an industry conference on Wednesday.
My Dividend Stock Portfolio: $10,000 In Dividends In 2024 - 97 Holdings With 13 Buys
08:10am, Wednesday, 15'th Jan 2025
In December, I invested around $1,200 primarily in Business Development Companies, boosting my annual dividend income by $131 with a full-year total of almost $1,700.
AbbVie Falls 8% in 3 Months: Buy, Hold or Sell the Stock?
12:25pm, Tuesday, 14'th Jan 2025
Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.
